A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC
The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with chemotherapy in the first-line treatment of advanced in NSCLC patients.
Non-small Cell Lung Cancer
DRUG: Carrelizumab + chemotherapy + apatinib
Progression-free survival, From the date Into this study to tumor progression or death for any, 1 Year
Overall survivalï¼Œ, The time from the beginning of treatment to the death of the subject due to various reasons, calculated by the intended treatment population (ITT), 2 Year|Objective response rate, it is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR., 2 Year|Disease Control Rate, the rate of CR, PR plus SD, 2 Year|Duration of Response, Cr or PR to the first assessment of PD or death from any cause, 2 Year
The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with chemotherapy in the first-line treatment of advanced in NSCLC patients.